Nant Health LLC, the biomolecular medicine company run by a Los Angeles billionaire entrepreneur, said Tuesday it sees its stock pricing between $12.50 and $15.50 a share in its coming initial public offering.

Patrick Soon-Shiong, chairman and chief executive of Nant Health, is a biotech investor, physician and scientist. He is widely known as one of the richest people in Los Angeles, thanks to his innovations in the health-care sector, from pioneering treatments for multiple forms of cancer to technological advancements in artificial intelligence.

He sold two biotech startups in 2008 and 2010 that he had launched, together worth roughly $8 billion. On Monday, he took a 13% stake in Tribune Publishing Co. for $70.5 million, becoming an ally to the newspaper owner as it fights against an unsolicited takeover bid from Gannett Co.

In a regulatory filing Tuesday, Nant Health said it plans to sell 6.5 million shares, plus up to 975,000 shares in a so-called overallotment option, which gives underwriters the opportunity to sell additional shares under certain circumstances. The company could be worth as much as $1.83 billion after the offering.

Nant Health said it expects to earn $81.6 million from the sale, assuming that the stock prices at the midpoint of its range and after deductions for underwriting discounts and commissions, as well as offering expenses. If the underwriters exercise their option to purchase additional shares in full, the company estimates proceeds of $94.3 million.

Nant Health is a subsidiary of Dr. Soon-Shiong's NantWorks, a company devoted to applying advanced technology into different industries such as science, commerce and communication.

The company said Dr. Soon-Shiong is estimated to control roughly 58% of the voting power in Nant Health after the offering. Some of Nant's existing investors, including entities affiliated with Dr. Soon-Shiong and biopharma company Celgene Corp., indicated an interest in purchasing up $70 million worth of shares in this offering.

The company has applied to list on the Nasdaq exchange under the ticker symbol NH.

Write to Joshua Jamerson at joshua.jamerson@wsj.com

(END) Dow Jones Newswires

May 24, 2016 10:15 ET (14:15 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.